Savara Inc
SVRA3.950USD
-0.030-0.75%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
682.71MMarket Cap
LossP/E TTM
More Details of Savara Inc Company
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Savara Inc Info
Ticker SymbolSVRA
Company nameSavara Inc
IPO dateJun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
Number of employees59
Security typeOrdinary Share
Fiscal year-endJun 25
Address6836 Bee Cave Road
CityAUSTIN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code78746
Phone151285113796
Websitehttps://savarapharma.com/
Ticker SymbolSVRA
IPO dateJun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
Company Executives of Savara Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
12.44%
Bain Capital Life Sciences Investors, LLC
8.95%
Deerfield Management Company, L.P.
6.90%
TCG Crossover Management, LLC
6.29%
Frazier Life Sciences Management, L.P.
5.83%
Other
59.59%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
12.44%
Bain Capital Life Sciences Investors, LLC
8.95%
Deerfield Management Company, L.P.
6.90%
TCG Crossover Management, LLC
6.29%
Frazier Life Sciences Management, L.P.
5.83%
Other
59.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.98%
Hedge Fund
20.01%
Venture Capital
18.26%
Investment Advisor/Hedge Fund
14.30%
Private Equity
5.83%
Corporation
3.46%
Individual Investor
2.45%
Research Firm
0.47%
Bank and Trust
0.27%
Other
4.97%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
286
169.85M
86.94%
-21.45M
2025Q2
295
181.81M
105.19%
-8.48M
2025Q1
306
176.74M
102.29%
-9.64M
2024Q4
294
173.80M
101.27%
-5.45M
2024Q3
274
169.68M
103.28%
+3.87M
2024Q2
257
157.29M
95.89%
+28.15M
2024Q1
230
131.01M
94.21%
-92.17K
2023Q4
197
123.19M
91.03%
-2.15M
2023Q3
177
120.11M
89.27%
+14.67M
2023Q2
170
92.45M
81.05%
-2.68M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
24.47M
14.16%
--
--
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
17.60M
10.18%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
7.96M
4.61%
--
--
Jun 30, 2025
TCG Crossover Management, LLC
12.36M
7.15%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
11.46M
6.63%
--
--
Jun 30, 2025
Vestal Point Capital, LP
11.02M
6.37%
+15.00K
+0.14%
Jun 30, 2025
VR Adviser, LLC
8.88M
5.14%
+5.63M
+172.72%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.54M
4.94%
-164.33K
-1.89%
Jun 30, 2025
Nantahala Capital Management, LLC
8.33M
4.82%
+250.00K
+3.10%
Jun 30, 2025
The Vanguard Group, Inc.
8.43M
4.88%
+334.73K
+4.13%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Texas Capital Texas Small Cap Equity Index ETF
0.21%
iShares Micro-Cap ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Texas Capital Texas Equity Index ETF
0.05%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.01%
iShares Morningstar Small-Cap ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.14%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Texas Capital Texas Equity Index ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Morningstar Small-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
